Speculation on the CEO.ca chat board.
The company may have the $6B Rova-T drug in their sights!
This advanced stage chemotherapy drug failed in late stage human trials due to off target toxicity.
$APC's patents in conjugation has been showed to perform up to 15x better than chemo's without the $APC Conjugation linking their chemotherapy.
If AbbVie and $APC come together to research and develop this potential. There could be some massive funding and licensing potential ahead.
To put it in layman's terms. $APC reduces the harshness of cancer treatments by being able to site specifically target the host, as well as by not breaking down enroute to the host. So more toxins can hit the target and less toxins can hit the healthy cells. It's a breakthrough the likes of which can save countless lives! As many patients are denied potentially life saving chemo, because the chemo itself is too harsh on the body and could kill an elderly person.
$100m market cap here by year end is my best guess. If this Rova-T speculation is executed. That may be a very conservative number.
Looking solid to break into new heights next week! With the Harvard/Yale/Columbia/Tufts educated people driving the ship here stateside. There is a lot of blue sky to look forward to around the corner!!